CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones

CytomX Therapeutics, Inc.

CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.
Tiered royalties from high single digit to low-teen percentages on global net sales of licensed products.
Collaboration uses CytomX's Probody platform and Regeneron's Veloci-Bi bispecific platform for conditionally-activated cancer therapies.
Regeneron fully funds all preclinical, development, manufacturing, and commercialization activities worldwide.
CytomX grants exclusive worldwide royalty-bearing license to Regeneron for oncology; Regeneron may terminate programs on 30 days' notice after 2 years.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with Regeneron Pharmaceuticals Inc. valued at $30 million (effective 2022-11-16).

Action: entry
Agreement: collaboration
Counterparty: Regeneron Pharmaceuticals Inc.
Value: $30 million
Effective: 2022-11-16

Exact text from the filing

On November 16, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with Regeneron Pharmaceuticals Inc. (“Regeneron”), pursuant to which the Company and Regeneron will collaborate on the creation of conditionally-activated investigational bispecific cancer therapies utilizing the Company’s Probody ® therapeutic platform and Regeneron’s Veloci-Bi ® bispecific antibody development platform.

View on SEC.gov

Browse all material agreements →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-290176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.